Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: American Spirit who wrote (46341)	6/24/1999 4:43:00 PM
From: HeatherN	Respond to of 120523

American Spirit, I'm not entirely sure that all the bad news is behind PFE. Here's a little something that I received regarding Celebrex vs. Vioxx. (Celebrex is PFE's cox-2 inhibitor that has been written about more in the Wall Street Journal than any medical publication that I get, Vioxx is Merck's). June 8,1999 IMS Health report prescription activity (edited) IMS Health today reports that 4,797 prescriptions were dispensed in the U.S. for Vioxx in the first 10 days of prescription activity. This compares to 3,231 written for Celebrex in Jan 1999 for the first ten days of prescription activity. eom. It was greatly touted as a success for Celebrex at the time to have so many prescriptions written in the first week or two. Also mentioned was the importance of being the first to market. As a significant prescriber of this class of medication, we are using Vioxx, not Celebrex when indicated. I don't think this will be a s fabulous for the bottom line as they had hoped. They do, however, maintain an army of the most aggressive reps ever (pitbulls I call then----not allowed in my office when I am there) and they have a good R&D pipeline. Just pointing out another view. HeatherN